CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 22, 2008 - Javelin Pharmaceuticals Inc. (AMEX: JAV) today announced that it recently received notification that it had been granted a commercially important Canadian patent with broad claims, enabling greater protection of Javelin's PMI-150 (intranasal ketamine). Canadian Patent Number 2,184,007 entitled: "Nasal and Ocular Administration of ketamine to manage Pain and for Detoxification" provides protection covering Javelin's intranasal ketamine drug into 2015.
Generally, Javelin's Canadian ketamine patent covers the use of nasally administered ketamine to treat chronic pain, as well as devices used to treat pain by nasal administration of ketamine. "The device claims are significant," said David Bernstein, Javelin's General Counsel and Chief Intellectual Property Counsel, "because they offer broad protection for the idea of using ketamine intranasally to treat pain, while also providing a readily enforceable focus on a device for controlling pain rather than a method."
"This new patent, directed to Javelin's anticipated commercial formulations of PMI-150, encompasses a broad range of claims that enhance our intellectual property portfolio and commercial protections for PMI-150 in Canada," said Dr. Daniel Carr Javelin's CEO/CMO. "We believe that upon approval, PMI-150 will be the only intranasal ketamine product offering physicians and patients a non-opioid alternative for treatment of moderate to severe pain," Dr. Carr added.
No comments:
Post a Comment